Prediction of survival and outcomes with depth of response at 6 months in metastatic non-small-cell lung cancer patients treated with chemotherapy and immunotherapy combination: SPORE trial | Synapse
Prediction of survival and outcomes with depth of response at 6 months in metastatic non-small-cell lung cancer patients treated with chemotherapy and immunotherapy combination: SPORE trial
The aim is to determine if depth of response at 6 months can predict overall survival in patients undergoing treatment for metastatic non-small-cell lung cancer.
Assessment of depth of response using RECIST 1.1 criteria
Focus on patients receiving first-line chemotherapy and immunotherapy
Evaluation of survival outcomes over a specified timeframe
Depth of response significantly predicts overall survival in treated patients
Positive correlation observed with deeper responses and improved survival rates
Abstract
Depth of response at 6 months according to RECIST 1.1 criteria for patients with mNSCLC still on first-line therapy is a predictor of overall survival.
Ask AI
Helpful
Bookmark
Share
View Full Paper
Ask AI
Helpful
Bookmark
Share
View Full Paper
Cite This Study
Moinard-Butot et al. (Thu,) studied this question.